Key takeaways
Insurance plans may stop covering GLP-1s for weight loss due to cost, generic availability, or changes in eligibility criteria.
If your insurance stopped covering Wegovy or another GLP-1, the first step is to contact your plan directly to find out the reason. This way, you can start an appeal with your healthcare provider. (As a Ro Body member, you can just contact our insurance concierge.)
If your appeal is denied, other options include paying cash for your GLP-1, discussing microdosing or off-label GLP-1s with your provider, or exploring other weight loss treatments.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Insurance plans may stop covering GLP-1s for weight loss due to cost, generic availability, or changes in eligibility criteria.
If your insurance stopped covering Wegovy or another GLP-1, the first step is to contact your plan directly to find out the reason. This way, you can start an appeal with your healthcare provider. (As a Ro Body member, you can just contact our insurance concierge.)
If your appeal is denied, other options include paying cash for your GLP-1, discussing microdosing or off-label GLP-1s with your provider, or exploring other weight loss treatments.
Has your insurance stopped covering Wegovy, Zepbound, or another GLP-1? If so, you’re not alone. It feels like insurance drug coverage can change on a whim.
Below, we explain why your insurance may have stopped covering GLP-1s for weight loss and share an action plan for re-securing coverage — or, at the very least, getting a more affordable price for your medication.
Reasons why insurance stopped covering your GLP-1 for weight loss
Insurance drug formularies (the list of drugs covered by a plan) can change from year to year. Here are five reasons why your insurance may have stopped covering your GLP-1 for weight loss:
A generic alternative may be available. Some insurance plans opt to only cover generic medications, especially when the brand-name version is expensive (as so many GLP-1s are). In late 2024, the US Food and Drug Administration (FDA) approved generic forms of Victoza (liraglutide) and Byetta (exenatide). In August 2025, the FDA approved a generic version of Saxenda (liraglutide). So, if you were taking Saxenda or Victoza (liraglutide drugs), for example, that may be why you lost coverage.
The price of your GLP-1 went up. Sometimes insurance plans drop coverage of a medication when the cost increases. For example, Blue Cross Blue Shield of Michigan cited cost as one of the reasons it dropped coverage of weight loss GLP-1s in 2025.
The drug may no longer be FDA-approved. If new safety evidence is released, a drug may lose its approval from the FDA and, thus, coverage from your insurance plan.
Your plan covers similar medications instead. Plans may cover different GLP-1s (and drugs, overall) for weight loss, especially if one drug is more affordable than another. For example, CVS Caremark stopped covering Zepbound in 2025 and directed patients to Wegovy instead.
You may no longer fit the insurance plan’s criteria. If you’ve lost enough weight on your GLP-1, you may no longer fit your insurance plan’s requirements for coverage — even if you want to keep using the medication for weight maintenance.
What to do if insurance stopped covering your GLP-1: 8 steps
If your insurance stopped covering your GLP-1s, consider following the step-by-step plan below. That is, unless you’re a Ro Body member. In that case, you can simply contact Ro’s insurance concierge, and they’ll handle the process for you.
1. Contact your insurance company to find out why
Your first step when your insurance stops covering your GLP-1 is to call them directly via the number on your insurance card and ask why. There could be a number of reasons, including:
Qualification requirements: You no longer meet the qualifications for coverage, such as losing a certain amount of weight or no longer having a weight-related condition.
Paperwork concerns: Your plan may require your healthcare provider to resubmit prior authorization after a certain time period, and that time has lapsed.
Formulary exclusions: Your insurance plan dropped the GLP-1 from its list of covered drugs. Formulary exclusions have risen significantly in recent years, especially for GLP-1s.
Generic availability: A generic has become available that your insurance plan has chosen to cover instead (if you’re okay with the generic, ask your healthcare provider if an Rx for that version is possible).
Clerical errors: Sometimes, things happen. It could be a random mistake that caused your loss of coverage, and now you can fix it.
After you find out why your insurance stopped covering your GLP-1, make sure to ask your insurance company or provider what’s required for you to appeal its decision. That brings us to the next step.
2. Contact your healthcare provider about an appeal
Once you know why your coverage has been denied, it’s time to submit an appeal. Here’s what to do:
Tell your healthcare provider why you were denied so they can start the paperwork. This may include a new prior authorization, letter of medical necessity, and clinical notes documenting your prior weight loss treatments.
Complete any additional forms required by your health insurance plan. Make sure to include your name, claim number, and health insurance ID number.
Submit everything as soon as possible. You have a limited amount of time to do this. For example, Medicare requires you to submit within 65 days of a coverage denial notice, while marketplace plans allow up to 180 days (six months).
Wait for their response. Insurance companies owe you a timely response. For Medicare, the standard process takes 7 days. For marketplace plans, it takes 30–60 days.
If your appeal is denied, you can try again. Or, you can move on to the following steps for other ways to save or get your insurance to cover your GLP-1.
3. See if you qualify for a different diagnosis
Sometimes, an insurance plan won’t cover a medication for weight loss but will cover it for another FDA-approved indication.
Go over the FDA-approved indications for your GLP-1 with your healthcare provider and consider whether you might be eligible to update your diagnosis for another condition instead.
Here’s a short list of other conditions that weight loss GLP-1s are approved to treat:
Cardiovascular risk reduction (Wegovy pill and injection)
Fatty liver disease (Wegovy injection)
Obstructive sleep apnea (Zepbound)
4. Check if you’re eligible for any manufacturer savings programs
If your insurance stopped covering Wegovy or another GLP-1, you may still be eligible to save using the drug’s manufacturer savings program. For example, if you have commercial drug insurance that doesn’t cover Zepbound, Lilly has an offer that can save you up to $620 per month.
5. Explore cash-pay options
Some GLP-1s for weight loss — including Wegovy and Zepbound — are now available for much lower prices when bought directly through the manufacturer or its official partners like Ro.
When prescribed and purchased via cash-pay on Ro:
Wegovy pill costs $149–$299 per month, depending on the dose
Wegovy injection costs $199–$349 per month, depending on the dose
Zepbound vials cost $299–$499 per month, depending on the dose
Zepbound injection costs about $1,050 per month
6. Look into pharmacy discount cards
If paying cash isn’t an option and you can only fill your prescription through your local pharmacy, you may still be able to save some money on your GLP-1. The following websites offer pharmacy-specific GLP-1 coupons you can use:
GoodRx
BuzzRx
SingleCare
OptumRx
WellRx
Here’s how to use a coupon: Visit the website, find your GLP-1 and prescribed dosage, and then download the coupon for your pharmacy. Present it to the pharmacist when you pick up your Rx.
7. Potentially talk to your provider about microdosing
One way some providers help their patients cut costs on GLP-1s is through microdosing. While the specifics may vary, GLP-1 microdosing generally refers to a non-standard dosing regimen in which you take smaller doses or wait longer between doses. This can allow you to stretch the same amount of medication over longer periods.
Microdosing is not officially recommended by drug manufacturers or well-researched. In fact, most of what is known about microdosing for weight loss comes from real-world reports, smaller studies, and clinical practice observations. There aren’t any large-scale clinical trials that support microdosing as a long-term weight management strategy.
However, limited research suggests that the tactic can still help you lose weight — to a lesser extent than the standard dosing regimen, that is. For example, a theoretical study found that switching from the recommended one dose per week of semaglutide or tirzepatide to one dose every other week could help you maintain about 75% of the weight loss achieved with standard dosing.
Important: Do not change your dosing regimen without first consulting your healthcare provider. If you’re considering microdosing, it is essential to do so under close medical supervision.
Note: Ro does not offer GLP-1 microdosing treatment at this time.
8. Consider other weight loss medications and treatments
If your budget won’t allow you to stick with your current GLP-1 without insurance, talk to your healthcare provider about other weight loss options that may be covered by your insurance plan.
Weight loss pills may be just as unlikely to be covered by insurance as GLP-1s for weight loss. But they may have lower out-of-pocket costs. Some options include:
Contrave (naltrexone/bupropion)
Qsymia (phentermine-topiramate)
Xenical (orlistat)
Depending on your body weight, you may be a candidate for weight loss surgery. Now, bariatric surgery can be expensive; 2023 estimates put the average cost at $10,900–$13,600. But the procedure may be significantly more likely to be covered by insurance, including Medicare and Medicaid.
Some research also suggests it can be more cost-effective and yield better long-term weight loss results than prescription medications, such as GLP-1s. But there’s no denying that surgery comes with its fair share of risks, potential side effects, recovery time, and other factors worth considering.
Cost of GLP-1s for weight loss without insurance
The exact price of GLP-1s without insurance varies, and can depend on the dosage and whether you go with a cash-pay option or a traditional pharmacy. While this doesn’t apply to all medications, in general:
Lower dosages can be more affordable than higher dosages (when purchased via cash-pay).
Cash-pay options tend to be more affordable than filling at the pharmacy.
Here’s a quick look at the average monthly cost of GLP-1s for weight loss without insurance:
Wegovy pill | Wegovy injection | Zepbound | Saxenda | |
List price | $1,349.02 | $1,349.02 | $1,086.37 (pens) | $1,349.02 |
Cash price | $149–$299, depending on dose | $199–$349, depending on dose | $299–$499, depending on dose (vials) $299–$699 (KwikPens) ~$1,050 per month (pens) | N/A |
GLP-1 alternatives for weight loss
If insurance stopped covering Wegovy or another GLP-1 for weight loss, you may want to consider alternatives, such as taking other GLP-1s off-label and Rx weight loss pills.
And while they’re not necessarily an alternative (because you should be following these practices while taking any drug for weight loss), you should also consider eating a healthy diet and doing regular exercise.
Other GLP-1s
If your insurance doesn’t cover GLP-1s for weight loss, it may still cover GLP-1s when prescribed for another indication. Sometimes providers prescribe these GLP-1s off-label for weight loss.
Victoza (liraglutide): a daily injection approved for type 2 diabetes that’s available in both branded and generic versions
Ozempic (semaglutide): a weekly injection approved for lowering blood sugar, reducing cardiovascular risk in type 2 diabetes, and slowing kidney decline in people with type 2 diabetes
Rybelsus (semaglutide): a daily pill approved for lowering blood sugar and cardiovascular risk in people with type 2 diabetes
Mounjaro (tirzepatide): a weekly injection approved for type 2 diabetes
Byetta (exenatide): a twice-daily injection approved for type 2 diabetes that’s available in both branded and generic versions
Trulicity (dulaglutide): a weekly injection approved for lowering blood sugar and cardiovascular risk in type 2 diabetes
It’s worth noting that since these GLP-1s aren’t approved for weight loss, their weight loss results are typically less than those caused by GLP-1s for weight loss. The one exception is Mounjaro, which contains the same active ingredient and dosage strengths as Zepbound.
Even so, you and your provider may decide that these can be a good alternative for helping you maintain the weight you’ve lost or keep losing more.
Non-GLP-1 weight loss pills
Similar to GLP-1s, prescription weight loss pills aren’t always covered by insurance plans. However, some may be covered by your insurance plan or have a lower out-of-pocket cost, making them a decent alternative.
Plus, research shows that people who switch to these medications after a year on GLP-1s are able to maintain their original weight loss — or lose even more.
Lomaira (phentermine): a daily pill approved for short-term use (up to 12 weeks) that’s available in both branded and generic versions
Xenical (orlistat): a thrice-daily pill approved for long-term use that’s available in both branded and generic versions and as a lower-strength over-the-counter treatment (Alli)
Contrave (naltrexone/bupropion): a twice-daily pill approved for long-term use
Qsymia (phentermine-topiramate): a daily pill approved for long-term use that’s available in both branded and generic versions
Keep up with diet and exercise
Finally, it’s important to keep up with the lifestyle changes you started while taking your GLP-1 — namely, diet and exercise. Studies show that people who maintain a healthy, low-calorie diet and regular physical activity are more likely to keep off the weight they lost while taking GLP-1s.
Bottom line
Insurance plans can pick and choose which medications they cover — and oftentimes, GLP-1s aren’t included, especially when they’re for weight loss and management. If your insurance stopped covering Wegovy, Zepbound, or another GLP-1, here’s what to remember:
There’s usually a reason why insurance stops covering GLP-1s. A generic may be available, your GLP-1 went up in cost, your plan covers another, lower-priced medication instead, or you no longer meet their criteria for coverage.
You can appeal their decision. Call your insurance company to find out why your coverage was denied and how the appeal process works. Or if you’re a Ro Body member, simply reach out to Ro’s insurance concierge for help.
Your healthcare provider is your partner in this process. Work with them to appeal the coverage denial or consider other cost-saving options, such as switching to another medication that is covered.
Some GLP-1s for weight loss are now more affordable without insurance thanks to today’s cash-pay options. If prescribed on Ro, for example, you can get Wegovy (pen and pill) at a cash price of $149–$349 and Zepbound (vials) at $299–$499, depending on dose.
Frequently asked questions (FAQs)
What to do if your insurance stopped covering Wegovy?
If your insurance plan stopped covering Wegovy, your first step is to call your plan directly to find out the reason(s). Your healthcare provider may need to submit prior authorization or help you appeal their decision. If you’re a Ro Body member, you can simply contact Ro’s insurance concierge, and they’ll handle the process for you.
What is the cheapest GLP-1 without insurance?
The cheapest GLP-1 for weight loss without insurance is the Wegovy pill, which costs $149–$299 per month, depending on dose, on Ro (if eligible).
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
References
Barrett, T. S., Hafermann, J. O., Richards, S., et al. (2025). Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surgery, 160(11), 1232. doi:10.1001/jamasurg.2025.3590. Retrieved from https://jamanetwork.com/journals/jamasurgery/fullarticle/2839126
Cengiz, A., Wu, C. C., & Lawley, S. D. (2025). Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes, Obesity & Metabolism, 27(4), 2251–2258. doi:10.1111/dom.16229. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11885104/
CVS Caremark. (2025). Enabling wider access to effective weight management treatment. Retrieved from https://business.caremark.com/what-we-do/cost-management/formulary/glp-1s.html
Drugs.com. (2026). Wegovy coupon card: Do I qualify and how much can I save? Retrieved from https://www.drugs.com/medical-answers/wegovy-coupon-card-qualify-how-save-3578459/
Eli Lilly. (2026). How much should I expect to pay for Zepbound (tirzepatide)? Retrieved from https://pricinginfo.lilly.com/zepbound
Gasoyan, H., & Sarwer, D. B. (2022). Addressing insurance‐related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery. Obesity, 30(12), 2338–2339. doi:10.1002/oby.23556. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9691525/
HealthCare.gov. (n.d.). Appealing a health plan decision. Retrieved from https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., et al. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 69, 102475. doi:10.1016/j.eclinm.2024.102475. Retrieved from https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00054-3/fulltext
Klein, H. E. (2024). Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden. The American Journal of Managed Care, 30(Spec No. 10), SP781–SP782. doi:10.37765/ajmc.2024.89614. Retrieved from https://www.ajmc.com/view/rising-costs-lead-insurers-to-drop-weight-loss-drug-coverage-further-increasing-patient-burden
Komé, A. M., Chandran, M. M., Tungate Lopez, S. S., Buse, J. B., & Klein, K. R. (2025). One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens. Diabetes Care, 48(3), e25–e27. doi:10.2337/dc24-2575. Retrieved from https://diabetesjournals.org/care/article/48/3/e25/157716/One-Size-Does-Not-Fit-All-Understanding
Mass.gov. (2026). CVS Caremark decides to remove Zepbound from CVS Caremark formulary. Retrieved from https://www.mass.gov/news/cvs-caremark-decides-to-remove-zepbound-from-cvs-caremark-formulary
Medicare.gov. (n.d.). Appeals in a Medicare drug plan. Retrieved from https://www.medicare.gov/providers-services/claims-appeals-complaints/appeals/drug-plans
Mounjaro.com. (2026). Coverage Authorization Requests and Appeals Guide. Retrieved from https://mounjaro.lilly.com/assets/pdf/sample-letter-of-medical-necessity.pdf
National Association of Insurance Commissioners (NAIC). (n.d.). Understanding Health Care Bills: What Is Medical Necessity? Retrieved from https://content.naic.org/sites/default/files/consumer-health-insurance-what-is-medical-necessity.pdf
Ng, A. P., Bakhtiyar, S. S., Verma, A., et al. (2023). Cost variation in bariatric surgery across the United States. The American Surgeon, 89(10), 4061–4065. doi:10.1177/00031348231177937. Retrieved from https://pubmed.ncbi.nlm.nih.gov/37203440/
Novo Nordisk. (2026). Price guide. Retrieved from https://www.novocare.com/content/dam/novonordisk/novocare/redesign/pdf/Wegovy_Price_Guide.pdf
Novo Nordisk. (2023). What is the list price for Saxenda and will it impact me? Retrieved from https://www.novocare.com/obesity/products/saxenda/explaining-list-price.html
Paddu, N. U., Lawrence, B., Wong, S., et al (2024). Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study. Obesity, 32(12), 2255–2263. doi:10.1002/oby.24177. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11589535/
Reiss, A. B., Gulkarov, S., Lau, R., et al. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules, 15(3), 408. doi:10.3390/biom15030408. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11940170/
Sydor, A. M., Bergin, E., Kay, J., et al. (2024). Modeling the effects of formulary exclusions: How many patients could be affected by a specific exclusion? Journal of Health Economics and Outcomes Research, 11(1), 86–93. doi:10.36469/001c.94544. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10970716/
Tchang, B. G., Aras, M., Kumar, R. B., et al. (2024). Pharmacologic treatment of overweight and obesity in adults. Endotext. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK279038/
Teva Investor Relations. (2025). Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss. Retrieved from https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx
US Food and Drug Administration (FDA). (2024). FDA News Release: FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes
US Food and Drug Administration (FDA). (2025). Highlights of Prescribing Information: Byetta (exenatide) Injection. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021773Orig1s051correctedlbl.pdf
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Mounjaro (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s009lbl.pdf
US Food and Drug Administration (FDA). (2025). Highlights of Prescribing Information: Ozempic (semaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Rybelsus (semaglutide) tablets, for oral use / Ozempic (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213051s030lbl.pdf
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Saxenda (liraglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s025lbl.pdf
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Trulicity (dulaglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125469s065lbl.pdf
US Food and Drug Administration (FDA). (2025). Highlights of Prescribing Information: Victoza (liraglutide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s046lbl.pdf
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Wegovy (semaglutide) injection, for subcutaneous use / Wegovy (semaglutide) tablets, for oral use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
US Food and Drug Administration (FDA). (2026). Highlights of Prescribing Information: Zepbound (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s042lbl.pdf
Xie, Z., Yang, S., Deng, W., et al. (2022). Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical Epidemiology, 14, 1463–1476. doi:10.2147/clep.s391819. Retrieved from https://pubmed.ncbi.nlm.nih.gov/36510488/














